dexbrompheniramine (disomer) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
DEXBROMPHENIRAMINE is an alkylamine derivative with anticholinergic and sedative properties. It is a histamine H1-receptor antagonist that competes with histamine for the H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract. The antagonistic action of this agent blocks the activities of endogenous histamine, which subsequently leads to temporary relief from the negative histamine-mediated symptoms of an allergic reaction such as bronchoconstriction, vasodilation, increased capillary permeability and spasmodic contractions of the gastrointestinal smooth muscle. DEXBROMPHENIRAMINE as a part of combination medicine is used to treat symptoms of the common cold or seasonal allergies, including sneezing, runny or stuffy nose, and itchy, watery eyes.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Over the Counter
  • Delivery Methods: Oral
  • Pro Drug: No

Combination drugs

( dexbrompheniramine (disomer), pseudoephedrine (Benylin) - other names: brompheril, disobrom, disophrol )
|
( acetaminophen (tylenol), dexbrompheniramine (disomer), pseudoephedrine (Benylin) )

Alternative names

3-(4-bromophenyl)- n,n-dimethyl- 3-pyridin-2-yl-propan-1-amine | (+)-brompheniramine | (+)-brompheniramine maleate | (+)-brompheniraminum | d-brompheniramine | desbrofeniramina | dexbromfeniramina | dexbrompheniramin | dexbrompheniramine | dexbromphéniramine | dexbrompheniramine fumarate | dexbrompheniramine maleate | dexbrompheniraminum | disophrol | (+)-parabromdylamine | (r)-3-(4-bromophenyl)-3-(2-pyridyl)propyldimethylamine | (s)-brompheniramine | (s)-(+)-brompheniramine | w0027

Organizations (17)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (6)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (2)


 

Common Cold (approved 2005)

Rhinitis, Allergic (approved 2005)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Tinea Pedis (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue